


ITOG

2018 ANNUAL MEETING



LA BIOMED

Friday, April 27th

10:00 – 12:00 PM	Arrivals	Luskin CC
10:00 – 5:00 PM	Registration	Luskin CC
12:00 – 1:30 PM	Committee Meetings (<i>With Working Lunch</i>)	(<i>See Spec Program</i>)
1:30 – 6:00 PM	Los Angeles Scheduled Activities (Sign Up Required)	
2:00 – 5:00 PM	Board Meeting (<i>With Working Lunch</i>)	Luskin CC
6:30 – 8:30 PM	Welcome Reception Evening With Friends And Colleagues	Luskin CC

Saturday, April 28th UCLA FACULTY CENTER-SEQUOIA ROOM

6:30 – 12:00 PM	Registration	Sequoia Room
7:00 – 7:30 AM	<i>Breakfast</i>	Sequoia Room
7:25 – 7:30 AM	Welcome Presented by Wendy Sacks / Andrew Gianoukakis	
7:30 – 8:30 AM	SESSION I: Beyond the tumor in Cancer Research	
7:30 – 7:50 AM	Neural regulation of the cancer genome	Steve Cole
7:50 – 8:10 AM	The microbiome in cancer development, progression and response to therapy	Sandip Patel
8:10 – 8:30 AM	Lifestyle and breast cancer incidence and outcome	Rowan Chlebowski
8:35 – 9:35 AM	SESSION II: Onco-Metabolism and Tumor Microenvironment	

8:35 – 8:55 AM	Cell extrinsic control of metabolism in cancer	Peter Mullen
8:55 – 9:15 AM	Mitigating metabolic changes associated with Ras activity and high fat diet in reducing tumor size, lessons from prostate cancer	Neil Bhowmick
9:15 – 9:35 AM	Highly multiplexed imaging of the tumor immune microenvironment	Akil Merchant
9:35 – 9:55 AM	<i>Break</i>	
9:55 – 11:15 AM	SESSION III: Thyroid Cancer Genomics and Signaling	
9:55 – 10:15 AM	Genome evolution in Hurthle cell carcinoma	David McFadden
10:15 – 10:35 AM	Integrated genomic analysis of Hurthle cell carcinoma reveals novel oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes	Ian Ganly
10:35 – 10:55 AM	Discriminating oncogenic states using the OncoGPS analytic framework: applications in thyroid cancer	Bharat Panuganti
10:55 – 11:15 AM	Preclinical models of drug resistance in thyroid cancer	Carmelo Nucera
11:20 – 12:30 AM	SESSION IV: Management of Papillary Thyroid Micro-Carcinoma: Hands-off?	
11:20 – 11:40 AM	Management of Papillary Thyroid Micro-carcinoma (<i>PTMC</i>)	Akira Miyauchi
11:40 – 12:00 AM	Active surveillance of Thyroid Micro-carcinoma	YongKee Shong
12:00 – 12:20 AM	Proper patient selection for active surveillance of low risk thyroid cancer	Mike Tuttle
12:20 – 12:30 AM	Moderated Panel	Allen Ho
12:30 – 2:30 PM	Working Lunch (<i>See Spec Program</i>) Business Meeting/Active trial update/ITOG Open Discussion Group Photo/UCLA CAMPUS TOUR	
2:30 – 3:35 PM	SESSION V: Challenges in Cancer Treatment	
2:30 – 2:50 PM	Tumor heterogeneity and resistance	Ravi Salgia

2:50 – 3:10 PM	Response and resistance to PD-1 blockade therapy in cancer	Antoni Ribas
3:10 – 3:15 PM	Gagel Award Introduction	Alan Ho
3:15 – 3:35 PM	The role of myeloid-derived suppressor cells in the response to targeted therapies in advanced thyroid cancer	Sareh Parengi
3:40 – 5:00 PM	SESSION VI: Emerging concepts-Anaplastic Thyroid Cancer	
3:40 – 3:55 PM	ATC Clinical Trials: Current status of recent, ongoing and planned trials	Eric Sherman
3:55 – 4:10 PM	Seminal/recent developments in ATC: Tumor mutations, Microenvironment and Immunology	Maria Cabanillas
4:10 – 4:25 PM	Update on ATC Radiobiology/Radiosensitization	Manisha Shah
4:25 – 4:35 PM	International Rare Cancer Initiative	Alan Ho
4:35 – 5:00 PM	Moderated Panel Discussion	David Pfister
5:00 – 5:10 PM	<i>Break</i>	
5:10 – 6:00 PM	Industry Partner Session (See Spec program)	
6:00 – 6:30 PM	<i>Break</i>	
6:30 – 9:30 PM	ITOG MEMBERS ONLY <i>(Closed to industry representatives)</i>	
6:30 – 9:30 PM	Annual ITOG Dinner <i>(See Spec Program)</i>	Faculty Center/ California Room
6:30 – 9:30 PM	Rick Abrams Memorial Lectures	David Meyer/ Dennis Slamon/ Clive Svendsen
6:30 – 9:30 PM	Passing of the ITOG leadership baton	Lori Wirth- Manisha Shah

Sunday, April 29th LUSKIN CONFERENCE CENTER-Laureate Room

7:00 - 7:30 AM	<i>Breakfast</i>	Luskin CC
7:30 - 9:30 AM	SESSION VII: Therapeutic Forefront of Thyroid Cancer	
7:30 - 7:45 AM	Coexisting BRAF V600E and TERT Promoter Mutations: Implications in Thyroid Oncology	MingZhao Xing
7:45 - 8:00 AM	Neoadjuvant Vemurafenib for BRAF mutated PTC	Maria Cabanillas
8:00 - 8:15 AM	Selective RET inhibition with LOX0-292 in RET-altered Thyroid Cancer Patients	Lori Wirth
8:15 - 8:30 AM	Clinical activity of BLU-667, a highly potent and selective RET inhibitor in advanced, RET-altered thyroid cancer	Mimi Hu
8:40 - 8:55 AM	Phase I/II clinical trials with lenvatinib/pembrolizumab - toxicity and efficacy in non-thyroid solid tumors	Mathew Taylor
8:55 - 9:10 AM	MLN0128, a second generation mTOR inhibitor in differentiated and anaplastic thyroid cancer: Update on a phase II study	Jochen Lorch
9:10 - 9:25 AM	Genomic insights from a large gene variant and fusion panel	Rick Kloos/ Giulia Kennedy
9:30 - 9:45 AM	<i>Break</i>	
9:45 - 11:00 AM	SESSION VIII: Future Food For Thought- Luskin	
9:45 - 10:00 AM	Martinique Principles	Victor Bernet
10:00 - 10:15 AM	Enhancement of atf4 expression as a therapeutic strategy for medullary thyroid carcinoma	Rozita Yarmand/ Robert Gagel
10:15 - 10:30 AM	Postsurgical adjuvant treatment with lanreotide in node positive resected medullary thyroid cancer	Mike Demeure
10:30 - 10:45 AM	Potential future itog-fda interactions	Mike Menefee
10:45 - 11:00 AM	Discussion	
11:00 AM	Closing remarks	Wendy Sacks/ Andrew Gianoukakis
11:15AM	<i>Packed lunch/airport shuttle departure</i>	

FACULTY

ITOG MEMBER FACULTY

Victor J. Bernet, MD

Chair, Division of Endocrinology, Mayo Clinic – Jacksonville, FL

Maria E. Cabanillas, MD

Associate Professor, MD Anderson Cancer Center

Mike J. Demeure, MD

Program Director, Precision Medicine, Hoag Health Center

Bob F. Gagel, MD

Professor, MD Anderson Cancer Center

Andrew G. Gianoukakis, MD

Professor, Los Angeles BioMedical Research Institute (LA BioMed) at Harbor-UCLA

Alan L. Ho, MD, PhD

Assistant Attending, Memorial Sloan-Kettering Cancer Center

Richard T. Kloos, MD

Senior Medical Director, Veracyte

Jochen H.M. Lorch, MD, MSc

Dana Farber Cancer Institute

David G. McFadden, MD, PhD

Assistant Professor, UT Southwestern Medical Center

Mike Menefee, MD, PhD

Medical Officer, Federal Drug Administration

Carmelo Nucera, MD

PhD, Assistant Professor, Beth Israel Deaconess Medical Center

Sareh Parangi, MD

Professor, Massachusetts General Hospital

David G. Pfister, MD

Chief, Head & Neck Medical Oncology, Memorial Sloan-Kettering Cancer Center

Wendy Sacks, MD

Endocrinology, Cedars Sinai Medical Center

Manisha H. Shah, MD

Professor, Ohio State University

Eric Sherman, MD

Associate Attending, Memorial Sloan-Kettering Cancer Center

Matthew Taylor, MD

Assistant Professor, Oregon Health and Science University

Michael Tuttle, MD

Clinical Director, Endocrinology, Memorial Sloan-Kettering Cancer Center

Lori J. Wirth, MD

Medical Director, Center for Head & Neck Cancers, Massachusetts General Hospital

Mingzhao Xing, MD, PhD

Professor, Johns Hopkins University

GUEST FACULTY

Neil Bhowmick, PhD

Professor, Director, Cancer Biology Program, Cancer Institute, Cedars Sinai Medical Center

Rowan T. Chlebowski, MD, PhD

Professor, Chief, Div. of Medical Oncology/Hematology, Harbor-UCLA Medical Center

Steve Cole PhD

Professor, UCLA School of Medicine

Ian Ganly MD, PhD, MS, FRCS, FRCS-ORL

Associate Professor, Memorial Sloan Kettering Cancer Center

Rozita Yarmand PhD

Assistant Professor, MD Anderson Cancer Center

Allen Ho, PhD

Assistant Professor, Co-Director, Thyroid Cancer Program, Cedars-Sinai Medical Center

Mimi Hu, MD

Associate Professor, University of Texas MD Anderson Cancer Center

Giulia C. Kennedy, PhD

Chief Scientific and Medical Officer, Veracyte

Akil Merchant, MD

Assistant Professor, Keck School of Medicine/USC/Norris Cancer Center

David Meyer PhD

Professor, President & Chief Executive Officer, Los Angeles BioMedical Research Institute (LA BioMed) at Harbor-UCLA

Akira Miyauchi, MD

Professor, President and COO, Kuma Hospital, Japan

Peter J. Mullen, PhD

Assistant Project Scientist, UCLA

Sandip P Patel, MD

Assistant Professor, UC San Diego Moores Cancer Center

Bharat Panuganti, MD, PGY-3

Otolaryngology-head and neck Surgery, UC San Diego

Antoni Ribas MD., PhD

Professor, UCLA, Dir. Tumor Immunology, Jonsson Comprehensive Cancer Ctr (JCCC)

Ravi Salgia MD, PhD

Chair in Medical Oncology, City of Hope Medical Center

YoungKee Shong, MD

Professor, Asan Medical Center, Seoul, Korea

Dennis J. Slamon MD, PhD

Professor, Chief, Division of Hematology/Oncology, UCLA, Dir. Revlon/UCLA Women's Cancer Research Program (JCCC).

Clive Svendsen, PhD

Professor, Board of Governors Regenerative Medicine Institute, Cedars Sinai Medical Center